Pfizer Gross Margin 2012-2025 | PFE
Current and historical gross margin for Pfizer (PFE) over the last 10 years. The current gross profit margin for Pfizer as of September 30, 2025 is %.
| Pfizer Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2025-09-30 | $62.79B | $46.08B | 73.39% |
| 2025-06-30 | $63.83B | $46.04B | 72.12% |
| 2025-03-31 | $62.46B | $45.15B | 72.28% |
| 2024-12-31 | $63.63B | $45.78B | 71.94% |
| 2024-09-30 | $60.43B | $40.93B | 67.73% |
| 2024-06-30 | $56.22B | $32.71B | 58.18% |
| 2024-03-31 | $55.95B | $32.50B | 58.09% |
| 2023-12-31 | $59.55B | $34.60B | 58.10% |
| 2023-09-30 | $70.12B | $43.08B | 61.44% |
| 2023-06-30 | $79.27B | $55.43B | 69.93% |
| 2023-03-31 | $94.00B | $64.75B | 68.89% |
| 2022-12-31 | $101.18B | $66.83B | 66.05% |
| 2022-09-30 | $99.88B | $65.45B | 65.53% |
| 2022-06-30 | $101.28B | $62.98B | 62.18% |
| 2022-03-31 | $92.43B | $55.79B | 60.35% |
| 2021-12-31 | $81.29B | $50.47B | 62.08% |
| 2021-09-30 | $68.88B | $45.08B | 65.45% |
| 2021-06-30 | $55.12B | $39.25B | 71.21% |
| 2021-03-31 | $46.08B | $35.38B | 76.78% |
| 2020-12-31 | $41.65B | $33.17B | 79.63% |
| 2020-09-30 | $32.07B | $25.85B | 80.62% |
| 2020-06-30 | $34.47B | $27.66B | 80.24% |
| 2020-03-31 | $37.87B | $30.31B | 80.03% |
| 2019-12-31 | $40.91B | $32.85B | 80.31% |
| 2019-09-30 | $40.22B | $31.79B | 79.05% |
| 2019-06-30 | $40.84B | $32.32B | 79.14% |
| 2019-03-31 | $41.04B | $32.18B | 78.42% |
| 2018-12-31 | $40.83B | $31.84B | 77.99% |
| 2018-09-30 | $53.37B | $41.94B | 78.59% |
| 2018-06-30 | $53.24B | $41.66B | 78.25% |
| 2018-03-31 | $52.67B | $41.35B | 78.50% |
| 2017-12-31 | $52.55B | $41.32B | 78.63% |
| 2017-09-30 | $52.47B | $41.29B | 78.68% |
| 2017-06-30 | $52.35B | $40.92B | 78.17% |
| 2017-03-31 | $52.60B | $40.66B | 77.30% |
| 2016-12-31 | $52.82B | $40.50B | 76.67% |
| 2016-09-30 | $53.24B | $40.72B | 76.48% |
| 2016-06-30 | $52.29B | $40.63B | 77.71% |
| 2016-03-31 | $50.99B | $40.33B | 79.09% |
| 2015-12-31 | $48.85B | $39.20B | 80.25% |
| 2015-09-30 | $47.92B | $38.98B | 81.35% |
| 2015-06-30 | $48.20B | $39.11B | 81.14% |
| 2015-03-31 | $49.12B | $39.75B | 80.92% |
| 2014-12-31 | $49.61B | $40.03B | 80.69% |
| 2014-09-30 | $50.05B | $40.38B | 80.68% |
| 2014-06-30 | $50.33B | $40.74B | 80.95% |
| 2014-03-31 | $50.53B | $41.16B | 81.46% |
| 2013-12-31 | $51.58B | $42.00B | 81.42% |
| 2013-09-30 | $50.88B | $41.69B | 81.95% |
| 2013-06-30 | $51.19B | $41.98B | 82.02% |
| 2013-03-31 | $52.18B | $42.84B | 82.10% |
| 2012-12-31 | $54.66B | $44.84B | 82.03% |
| 2012-09-30 | $53.25B | $43.99B | 82.61% |
| 2012-06-30 | $56.90B | $46.54B | 81.80% |
| 2012-03-31 | $59.42B | $47.87B | 80.56% |
| 2011-12-31 | $61.04B | $48.54B | 79.52% |
| 2011-09-30 | $65.06B | $51.27B | 78.81% |
| 2011-06-30 | $64.44B | $50.28B | 78.02% |
| 2011-03-31 | $65.09B | $50.81B | 78.06% |
| 2010-12-31 | $65.17B | $50.38B | 77.31% |
| 2010-09-30 | $65.50B | $50.32B | 76.82% |
| 2010-06-30 | $61.13B | $47.95B | 78.44% |
| 2010-03-31 | $54.98B | $43.73B | 79.53% |
| 2009-12-31 | $49.27B | $40.81B | 82.83% |
| 2009-09-30 | $45.82B | $39.15B | 85.45% |
| 2009-06-30 | $46.17B | $39.17B | 84.84% |
| 2009-03-31 | $47.32B | $39.78B | 84.08% |
| 2008-12-31 | $48.30B | $40.18B | 83.20% |
| 2008-09-30 | $48.82B | $39.80B | 81.52% |
| 2008-06-30 | $48.84B | $37.32B | 76.42% |
| 2008-03-31 | $47.79B | $36.45B | 76.28% |
| 2007-12-31 | $48.42B | $37.18B | 76.79% |
| 2007-09-30 | $48.15B | $37.32B | 77.51% |
| 2007-06-30 | $48.44B | $40.27B | 83.12% |
| 2007-03-31 | $49.10B | $41.24B | 84.00% |
| 2006-12-31 | $48.37B | $40.73B | 84.21% |
| 2006-09-30 | $47.37B | $40.28B | 85.03% |
| 2006-06-30 | $46.35B | $39.61B | 85.46% |
| 2006-03-31 | $46.06B | $39.35B | 85.43% |
| 2005-12-31 | $47.41B | $40.17B | 84.74% |
| 2005-09-30 | $47.20B | $40.43B | 85.66% |
| 2005-06-30 | $48.77B | $41.97B | 86.06% |
| 2005-03-31 | $49.59B | $42.80B | 86.31% |
| 2004-12-31 | $48.99B | $42.60B | 86.95% |
| 2004-09-30 | $51.57B | $43.12B | 83.61% |
| 2004-06-30 | $51.09B | $40.99B | 80.24% |
| 2004-03-31 | $48.72B | $38.39B | 78.81% |
| 2003-12-31 | $44.74B | $35.15B | 78.57% |
| 2003-09-30 | $40.01B | $32.54B | 81.33% |
| 2003-06-30 | $35.66B | $30.45B | 85.39% |
| 2003-03-31 | $33.05B | $28.92B | 87.50% |
| 2002-12-31 | $32.29B | $28.28B | 87.57% |
| 2002-09-30 | $29.03B | $25.89B | 89.18% |
| 2002-06-30 | $28.86B | $25.57B | 88.60% |
| 2002-03-31 | $29.19B | $25.65B | 87.87% |
| 2001-12-31 | $29.02B | $25.20B | 86.83% |
| 2001-09-30 | $31.14B | $25.52B | 81.95% |
| 2001-06-30 | $30.47B | $24.81B | 81.41% |
| 2001-03-31 | $29.84B | $24.14B | 80.92% |
| 2000-12-31 | $29.41B | $23.71B | 80.60% |
| 2000-09-30 | $25.81B | $21.48B | 83.21% |
| 2000-06-30 | $21.99B | $18.06B | 82.16% |
| 2000-03-31 | $18.78B | $15.56B | 82.86% |
| 1999-12-31 | $15.54B | $13.01B | 83.73% |
| 1999-09-30 | $14.90B | $12.58B | 84.43% |
| 1999-06-30 | $14.90B | $12.92B | 86.68% |
| 1999-03-31 | $14.24B | $12.14B | 85.28% |
| 1998-12-31 | $13.35B | $11.25B | 84.31% |
| 1998-09-30 | $12.39B | $10.11B | 81.61% |
| 1998-06-30 | $11.71B | $9.36B | 79.93% |
| 1998-03-31 | $11.09B | $8.82B | 79.49% |
| 1997-12-31 | $10.74B | $8.47B | 78.82% |
| 1997-09-30 | $10.99B | $8.77B | 79.79% |
| 1997-06-30 | $11.14B | $8.94B | 80.28% |
| 1997-03-31 | $11.31B | $9.10B | 80.48% |
| 1996-12-31 | $11.31B | $9.13B | 80.75% |
| 1996-09-30 | $10.89B | $8.86B | 81.37% |
| 1996-06-30 | $10.63B | $8.58B | 80.77% |
| 1996-03-31 | $10.37B | $8.24B | 79.49% |
| 1995-12-31 | $10.02B | $7.86B | 78.40% |
| 1995-09-30 | $9.58B | $7.34B | 76.63% |
| 1995-06-30 | $9.11B | $6.94B | 76.10% |
| 1995-03-31 | $8.64B | $6.60B | 76.40% |
| 1994-12-31 | $8.28B | $6.36B | 76.84% |
| 1994-09-30 | $7.97B | $6.12B | 76.83% |
| 1994-06-30 | $7.77B | $5.96B | 76.73% |
| 1994-03-31 | $7.59B | $5.81B | 76.55% |
| 1993-12-31 | $7.48B | $5.71B | 76.30% |
| 1993-09-30 | $7.44B | $5.62B | 75.54% |
| 1993-06-30 | $7.39B | $5.49B | 74.24% |
| 1993-03-31 | $7.34B | $5.38B | 73.27% |
| 1992-12-31 | $7.23B | $5.21B | 72.01% |
| 1992-09-30 | $7.13B | $5.02B | 70.35% |
| 1992-06-30 | $7.08B | $4.94B | 69.81% |
| 1992-03-31 | $7.02B | $4.85B | 69.19% |
| 1991-12-31 | $6.95B | $4.75B | 68.35% |
| 1991-09-30 | $6.89B | $4.64B | 67.45% |
| 1991-06-30 | $6.76B | $4.49B | 66.41% |
| 1991-03-31 | $6.62B | $4.34B | 65.51% |
| 1990-12-31 | $6.41B | $4.15B | 64.74% |
| 1990-09-30 | $6.12B | $3.96B | 64.69% |
| 1990-06-30 | $5.91B | $3.80B | 64.29% |
| 1990-03-31 | $5.72B | $3.65B | 63.90% |
| 1989-12-31 | $5.67B | $3.61B | 63.65% |
| 1989-09-30 | $5.55B | $3.52B | 63.45% |
| 1989-06-30 | $5.49B | $3.47B | 63.21% |
| 1989-03-31 | $5.52B | $3.48B | 62.95% |
| 1988-12-31 | $5.39B | $3.37B | 62.49% |
| 1988-09-30 | $5.29B | $3.28B | 62.04% |
| 1988-06-30 | $5.21B | $3.20B | 61.44% |
| 1988-03-31 | $5.10B | $3.14B | 61.49% |
| 1987-12-31 | $4.92B | $3.02B | 61.44% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $144.872B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1005.472B | 48.37 |
| Johnson & Johnson (JNJ) | United States | $492.436B | 19.69 |
| AbbVie (ABBV) | United States | $388.966B | 23.29 |
| Roche Holding AG (RHHBY) | Switzerland | $340.187B | 0.00 |
| Novartis AG (NVS) | Switzerland | $298.992B | 15.85 |
| Merck (MRK) | United States | $274.338B | 12.78 |
| Novo Nordisk (NVO) | Denmark | $262.587B | 15.40 |
| Sanofi (SNY) | France | $119.584B | 11.56 |
| Bayer (BAYRY) | Germany | $44.366B | 7.79 |
| Innoviva (INVA) | United States | $1.464B | 7.33 |